Obesity Surgery

, 18:854

Systemic Inflammation and Cardiovascular Risk Factors: Are Morbidly Obese Subjects Different?

  • Joel Faintuch
  • Patricia C. Marques
  • Luiz A. Bortolotto
  • Jacob J. Faintuch
  • Ivan Cecconello
Research Article



Systemic inflammation is a hallmark of obesity as well as of other chronic diseases, usually indicating increased cardiovascular risk; however, studies with arterial documentation in morbid obesity are extremely scarce. Aiming to analyze correlation between inflammatory markers, pulse-wave velocity (PWV), and intima-media thickness (IMT), a prospective study was designed.


Morbidly obese patients [n = 29, age 46.3 ± 5.2 years, 82.8% females (24/29), BMI 44.9 ± 5.2 kg/m2] with C-reactive protein/CRP > 5 mg/l but free from trauma, infection, inflammation, or cancer were enrolled in this study. All were clinically stable candidates for elective bariatric operation. Variables included comorbidities, metabolic profile, inflammatory and coagulatory markers, and arterial morpho-functional indices.


Patients suffered from arterial hypertension (72.4%), metabolic syndrome (58.6%), and other comorbidities, but PWV and IMT were less aberrant than expected. Univariate correlation confirmed worse prognosis for those with metabolic syndrome and other accepted clinical risk factors. Multivariate confirmation was achieved for triglycerides (PWV) and D-dimer (IMT), but not for CRP, serum amyloid A, or neutrophil count, which were reversed in certain circumstances.


(1) Metabolic syndrome, hyperglycemia, hypertriglyceridemia and D-dimer were positively correlated with arterial measurements, whereas inflammatory and coagulatory markers often exhibited paradoxical association; (2) stratification confirmed that at certain levels of systemic inflammation or body mass index, acute phase proteins and other markers became unreliable or shifted signals; (3) when controlled for blood pressure, PWV was only moderately elevated, and IMT remained normal; (4) taken together, these findings are consistent with a unique interaction between adiposity, inflammation, and cardiovascular risk in seriously obese subjects.


Morbid obesity Atherosclerosis Pulse wave velocity Intima media thickness Arterial stiffness Metabolic syndrome Arterial hypertension Diabetes Inflammation C-reactive protein 


  1. 1.
    Albert MA. Inflammatory biomarkers, race/ethnicity and cardiovascular disease. Nutr Rev. 2007;65(12 Pt 2):S234–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Pietrasik G, Goldenberg I, McNitt S, Moss AJ, Zareba W. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol. 2007 Feb;18(2):181–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med. 1995;333:677–85.PubMedCrossRefGoogle Scholar
  4. 4.
    Kraja AT, Province MA, Arnett D, Wagenknecht L, Tang W, Hopkins PN, et al. Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? Nutr Metab (Lond). 2007 Dec 21;4(1):28.CrossRefGoogle Scholar
  5. 5.
    Faintuch J, et al. Systemic inflammation in morbidly obese subjects: response to oral supplementation with alpha-linolenic acid. Obes Surg. 2007 Mar;17(3):341–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Chudek J, Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep. 2006;58 Suppl:81–8.PubMedGoogle Scholar
  7. 7.
    Herbert A, Liu C, Karamohamed S, Liu J, Manning A, Fox CS, et al. BMI modifies associations of IL-6 genotypes with insulin resistance: the Framingham Study. Obesity (Silver Spring). 2006 Aug;14(8):1454–61.CrossRefGoogle Scholar
  8. 8.
    Mitchell GF, Guo CY, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, et al. Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. Circulation. 2007 May 22;115(20):2628–36.PubMedCrossRefGoogle Scholar
  9. 9.
    Al Snih S, Ottenbacher KJ, Markides KS, Kuo YF, Eschbach K, Goodwin JS. The Effect of Obesity on Disability vs Mortality in Older Americans. Arch Intern Med. 2007;167:774–80.PubMedCrossRefGoogle Scholar
  10. 10.
    Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.Google Scholar
  11. 11.
    Drapeau V, Lemieux I, Richard D, Bergeron J, Tremblay A, Biron S, et al. Waist circumference is useless to assess the prevalence of metabolic abnormalities in severely obese women. Obes Surg. 2007 Jul;17(7):905–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Livingston EH, Chandalia M, Abate N. Do current body mass index criteria for obesity surgery reflect cardiovascular risk? Surg Obes Relat Dis. 2007;3:577–85.PubMedCrossRefGoogle Scholar
  13. 13.
    Cao JJ, Arnold AM, Manolio TA, Polak JF, Psaty BM, Hirsch CH, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation. 2007;116:32–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond). 2008;114:361–74.CrossRefGoogle Scholar
  15. 15.
    Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I. Human C-reactive protein promotes oxidized low-density lipoprotein uptake and matrix metalloproteinase-9 release in wistar rats. J Lipid Res. 2008 Feb 2 (in press).Google Scholar
  16. 16.
    Albuquerque LC, Narvaes LB, Maciel AA, Staub H, Friedrich M, Filho JR, et al. Intraplaque hemorrhage assessed by high-resolution magnetic resonance imaging and C-reactive protein in carotid atherosclerosis. J Vasc Surg. 2007;46:1130–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Nishimura M, Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C, et al. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation. 2008 Jan 15;117(2):216–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Shargorodsky M, Fleed A, Boaz M, Gavish D, Zimlichman R. The effect of a rapid weight loss induced by laparoscopic adjustable gastric banding on arterial stiffness, metabolic and inflammatory parameters in patients with morbid obesity. Int J Obes (Lond). 2006 Nov;30(11):1632–8.CrossRefGoogle Scholar
  19. 19.
    Uretsky S, Bangalore S, Messerli FH. Obesity and mortality: a poorly understood relationship. Am J Cardiol. 2007;99:876–87.PubMedCrossRefGoogle Scholar
  20. 20.
    Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-deHoff RM, Zhou Q, et al. C Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007;120:863–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Fonarow GC, Srikanthan P, Costanzo MR, Cintron GB, Lopatin M. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J. 2007;153:74–81.PubMedCrossRefGoogle Scholar
  22. 22.
    Kalantar-Zadeh K, Block G, Horwich T, et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004;43:1439–44.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Joel Faintuch
    • 1
  • Patricia C. Marques
    • 2
  • Luiz A. Bortolotto
    • 3
  • Jacob J. Faintuch
    • 4
  • Ivan Cecconello
    • 1
  1. 1.Department of GastroenterologyHospital das ClinicasSão PauloBrazil
  2. 2.Nutrology Residency ProgramHospital das ClinicasSão PauloBrazil
  3. 3.Heart InstituteHospital das ClinicasSão PauloBrazil
  4. 4.Department of Internal MedicineHospital das ClinicasSão PauloBrazil

Personalised recommendations